Biotech News Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Doc Bones	8/13/2008 8:51:29 AM
	of 7143

Sanofi Sues Over Taxotere August 13, 2008; Page B6 Sanofi-Aventis SA has begun legal action against Canadian generic-drug maker Apotex Inc., which is planning to sell a low-cost version of the cancer drug Taxotere in the U.S., a spokesman for the French pharmaceutical company said. In a lawsuit filed Aug. 8, Sanofi-Aventis claims Apotex has infringed two U.S. patents of the drug, which had €1.87 billion ($2.79 billion) in sales last year, making it Sanofi-Aventis's fourth best-selling product. Taxotere is used to treat breast, lung and prostate cancer. Sanofi-Aventis's action will trigger a 30-month stay, which will put on hold the approval of generic Taxotere by the Food and Drug Administration. This period will expire at the end of 2010, the Sanofi-Aventis spokesman said. Apotex couldn't be reached for comment. online.wsj.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next